Our team

Board of Directors

Luis Sánchez-Lafuente

Chairman

Former Chief Executive Officer and co-owner of Laboratorios Gelos, SA. President of AB Biotics, SA

Carles Domènech

Executive chairman

Executive Chairman, CSO and co-Founder of Ability Pharmaceuticals, SL

 

José Manuel Valadés

General secretary

Lawyer, partner and founder of the law firm Alliant Abogados

Miquel Àngel Bonachera

Chief executive officer and co-founder of AB Biotics, SA.
BSc/MSc in biochemistry and MBA.

Sergi Audivert

Chief executive officer and co-founder of AB Biotics, SA. 
BSc/MSc in food technology and MBA.

Sara Secall

Operating Partner & Life Sciences Investment Director of Inveready Asset Management

Estanislao Tejeda

Partner, Global Strategic Deals at NTT DATA Europe & LATAM

Shermaine Tilley

Managing Partner Funds I, II & III, CTILife Science Fund

PhD in biochemistry from the Johns Hopkins University School of Medicine, MBA from the University of Toronto

LATEST NEWS

11.03.2024

Press Release

AbilityPharma Announces € 7 Million Financing Round to Advance Development of its Clinical Phase 2b Autophagy Inducer ABTL0812 in Metastatic Pancreatic Cancer + info
02.06.2023

Press Release

Ability Pharmaceuticals announces the presentation of the phase 2a results of ABTL0812 as first-line therapy in patients with lung cancer at the ASCO 2023 Annual Meeting in Chicago + info
14.12.2022

Press Release

AbilityPharma Achieves the 30% of the Estimated Recruitment for their Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as a First-Line Therapy Treatment in Advanced Pancreatic Cancer + info
21.11.2022

Press Release

AbilityPharma Obtains 1,5M € of Non-Dilutive Funding from Next Generation EU Funds to Further Study the Anticancer Immunomodulatory Effects of ABTL0812 + info
10.11.2022

Press Release

AbilityPharma will attend LSX investical showcase in London to meet with key investors and venture capital firms + info
02.11.2022

Press Release

ABTL0812 shows potential against glioblastoma brain tumors + info
07.10.2022

Press Release

AbilityPharma Secures 2,2M € of Non-Dilutive Funding from the Ministry of Science & Innovation of the Government of Spain to Accelerate the Clinical Development and Regulatory Path of ABTL0812 + info
07.09.2022

Press Release

Carles Domènech, Executive Chairman & CEO of AbilityPharma, Will Attend ESMO Congress in Paris for a Meeting with some of the most Relevant Key Opinion Leaders (KOLs) in the Treatment of Pancreatic Cancer + info
29.06.2022

Press Release

AbilityPharma Will Attend ESMO World Congress on Gastrointestinal Cancer 2022 in Barcelona + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG